METHOD FOR PREDICTING RESPIRATORY EFFECTS OF BRONCHOPULMONARY DYSPLASIA IN CHILDREN Russian patent published in 2022 - IPC A61B5/08 G01N33/68 A61K31/56 A61P11/00 

FIELD: medicine.

SUBSTANCE: invention relates to the field of medicine, namely, to pulmonology, and can be used to predict respiratory effects of bronchopulmonary dysplasia in children above the age of 3. Anamnestic data, such as the sex of the patient and the nature of respiratory support, are evaluated. Additionally, the provided therapy with inhaled steroids at the intensive care and outpatient stages and the hereditary history of atopic respiratory diseases are considered, and the concentration of glutathione in the blood serum is determined. Based on the combination of the resulting data, the probability of the formation of chronic respiratory pathology in the outcome of bronchopulmonary dysplasia Y is determined by the formula Y = 100% - (1 / (1+e^-x))*100%, wherein e is the base of a natural logarithm, x is the sum of the vectors of predictors, equal to 1.06A-1.27B+1.44C+0.67D-0.79E-0.60F, wherein A is the sex of the child: male – 1 point, female – 0 points; B is the nature of respiratory support in the intensive care unit: time in the neonatal period on artificial lung ventilation – 1 point, time in the neonatal period on non-invasive lung ventilation by the method for constant positive pressure through nasal cannulas – 0 points; C is the inhalation therapy in the intensive care unit: prescription of inhaled corticosteroids at the stage of intensive care – 1 point; absence of therapy with inhaled corticosteroids at the stage of intensive care – 0 points; D is the inhalation therapy at the outpatient stage: daily continuous therapy with inhaled corticosteroids for at least 1 month at the outpatient stage – 1 point; non-regular therapy with inhaled corticosteroids at the outpatient stage, or therapy for at least 1 month, or none thereof – 0 points; E is the hereditary history of atopic respiratory diseases: burdened hereditary history of atopic respiratory diseases – 1 point, favourable hereditary history of atopic respiratory diseases – 0 points; F is the concentration of glutathione in the blood serum: concentration of oxidised glutathione above 2.0 mcmol/l and/or concentration of reduced glutathione above 4.0 mcmol/l – 1 point, concentration of oxidised glutathione below 2.0 mcmol/l and/or concentration of reduced glutathione below 4.0 mcmol/l – 0 points. If the value Y is greater than or equal to 50%, a risk of development of chronic respiratory pathology in the outcome of bronchopulmonary dysplasia is predicted in a child.

EFFECT: increase in the accuracy of predicting respiratory effects of bronchopulmonary dysplasia in children above the age of 3 due to the comprehensive evaluation of the catamnesis data and simultaneous evaluation of the current state of respiratory health of children with recent history of bronchopulmonary dysplasia.

1 cl, 2 dwg, 2 ex